+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cardiometabolic Disease Drug"

Cardiometabolic Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Cardiometabolic Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 47 Pages
  • Global
From
  • 1 Results (Page 1 of 1)
Loading Indicator

The Cardiometabolic Disease Drug market is a subset of the Cardiovascular Drugs market, focusing on drugs used to treat cardiometabolic diseases such as diabetes, obesity, and dyslipidemia. These drugs are used to reduce the risk of cardiovascular events, such as heart attack and stroke, by controlling blood sugar, cholesterol, and triglyceride levels. Commonly prescribed drugs include statins, ACE inhibitors, and GLP-1 agonists. The Cardiometabolic Disease Drug market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Pfizer, Novartis, Sanofi, Merck, and AstraZeneca. Show Less Read more